8-K: QT Imaging Uplists to Nasdaq Capital Market

QT Imaging Holdings, Inc. announced its common stock has been approved for listing on the Nasdaq Capital Market, with trading expected to commence on January 28, 2026.

Summary

• QT Imaging Holdings, Inc. received approval from Nasdaq for the uplisting of its common stock to the Nasdaq Capital Market.
• Trading on Nasdaq is expected to begin on January 28, 2026, under the ticker symbol QTI.
• The company had previously pursued this uplisting, subject to satisfying initial listing requirements.
• Dr. Raluca Dinu, CEO, highlighted this as a milestone representing relentless work to turn the company around, rebuild its business model, balance sheet, and cap table.
• QT Imaging met all Nasdaq Capital Market listing requirements, including financial, corporate governance, and regulatory criteria.
• The company returned to Nasdaq after less than one year of being delisted.

Sentiment

Score: 8

Explanation: The uplisting to Nasdaq is a significant positive corporate governance and strategic milestone, indicating a successful turnaround and improved market access. While no specific financial performance metrics are provided, the event itself is highly favorable for the company's future prospects and investor confidence.

Positives

• Approval for uplisting to the Nasdaq Capital Market, which is expected to increase visibility and expand the stockholder base.
• Successful satisfaction of all Nasdaq listing requirements, including financial, corporate governance, and regulatory criteria.
• Return to Nasdaq after less than one year of being delisted, indicating a successful turnaround effort.
• Uplisting aligns with the company's long-term strategic vision of expanding its global footprint and advancing technological innovation.
• Management expresses renewed focus on transforming breast health management through innovative, radiation-free imaging technology.

Risks

• Ability to meet initial and continuous listing requirements for the Nasdaq Capital Market.
• Ability to sell and deploy the QT Imaging Breast Acoustic CT Scanner.
• Ability to extend product offerings into new areas or products.
• Ability to commercialize technology.
• Unexpected occurrences that deter the full documentation and bring-to-market plan for products.
• Trends and fluctuations in the industry.
• Changes in demand and purchasing volume of customers.
• Unpredictability of suppliers.
• Ability to attract and retain qualified personnel and move product sales to production levels.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Uncertainty of projected financial information.
• Delays caused by factors outside of our control.
• Changes in our ability to successfully receive purchase orders and generate revenue under existing contracts with partners and distributors.
• Ability to realize the benefits of strategic partnerships.
• Identified material weakness in internal controls over financial reporting (including the timeline to remediate the material weakness).
• Rollout of the business and the timing of expected business milestones.
• Effects of competition on our future business.
• Ability to obtain and access financing in the future.
• Ability to pay our debt obligations as they come due.
• Other factors discussed in the company's reports and other documents filed with the SEC, including under the heading Risk Factors.

Future Outlook

The uplisting to Nasdaq is expected to increase visibility, expand the stockholder base, and support long-term value creation. The company aims to expand its global footprint and advance technological innovations, remaining committed to delivering sustained value through innovation, operational excellence, and disciplined growth.

Management Comments

• "We are very pleased to have received approval to reestablish our listing on the Nasdaq Capital Market."
• "This milestone represents relentless work to turn the company around, rebuild its business model, its balance sheet, cap table, rebuild the trust, and refocus on what truly matters."
• "Our team pushed through uncertainty with discipline, resilience, and belief, supported every step of the way by stockholders who stayed with us."
• "We returned to Nasdaq after less than one year of being delisted."
• "QT Imaging exists for a simple and deeply personal reason. Women deserve better options for breast imaging, earlier answers, and care that puts their safety and dignity first."
• "Everything we have done has been in service of bringing this technology out of the lab and into the hands of clinicians and the women they serve."
• "As a stronger company with a clear mission, we believe a Nasdaq listing increases our visibility, expands our stockholder base, and supports long term value creation."
• "We are proud of how far we have come and energized by what lies ahead."

Industry Context

The medical device industry, particularly in diagnostic imaging, is continuously evolving towards safer, more accessible, and patient-friendly technologies. QT Imaging's focus on radiation-free breast imaging aligns with a broader industry trend to reduce radiation exposure and enhance patient experience. An uplisting to Nasdaq can significantly elevate a company's profile within this competitive industry, potentially attracting greater investment and facilitating strategic partnerships for technology commercialization and market expansion.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased visibility, expanded stockholder base, potential for long-term value creation, and improved liquidity due to Nasdaq listing.
• Employees: Potential for increased morale and stability due to company's strategic progress and turnaround.
• Customers/Clinicians: Continued focus on bringing innovative breast imaging technology to market, aiming to provide better options for patient care.
• Regulatory Authorities: Compliance with Nasdaq's financial, corporate governance, and regulatory criteria.

Next Steps

• Common stock to commence trading on Nasdaq on January 28, 2026.
• Continued commitment to innovation, operational excellence, and disciplined growth.
• Further updates for investors as the company embarks on this new chapter.

Key Dates

Recommendation

The uplisting to Nasdaq is a significant positive development, indicating a successful turnaround and improved market access. This event enhances the company's visibility and potential for future growth. However, without specific recent financial performance data or forward-looking financial guidance in this filing, a 'buy' recommendation would be premature. The company still faces numerous risks, including commercialization challenges and the need to remediate material weaknesses in internal controls. A 'hold' position allows investors to observe how the company leverages its Nasdaq listing to drive operational and financial improvements.

Keywords

QT Imaging, QTI, Nasdaq, Uplisting, Capital Market, Medical Device, Breast Imaging, Radiation-Free, SEC Filing, 8-K, Corporate Governance, Stock Market, Healthcare Technology